RADA16 for Aquablation Day Case
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexMale
AgeNot listed
SponsorNYU Langone Health
About this trial
This is a pilot proof of concept single-arm study using PuraStat following Aquablation procedure to assess reduction of hematuria to allow for same day discharge.
The primary objective is to assess how PuraStat affects post-operative hematuria following Aquablation.
The secondary objective is to assess the number of patients discharged on the same day based on the hematuria criteria (Grade 0 and Grade I).
Eligibility criteria
Qualifiers
None
Disqualifiers
None
Trial design
Treatments tested in this trial
- PuraStat
Treatment groups
25 Participants
are divided into 1 treatment groupLocations
1NYU Langone Health10016, New YorkNew York, United States
Sponsors and collaborators
NYU Langone Health
Lead sponsor
Source ClinicalTrials.gov